<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="Simian Immunodeficiency Virus Infection of Rhesus Macaques Results in Delayed" exact="Zika" post="Virus Clearance SIV Infection of Macaques Delays Zika Virus"/>
 <result pre="in Delayed Zika Virus Clearance SIV Infection of Macaques Delays" exact="Zika" post="Virus Clearance Vinton et al. VintonCarol L.aMagazinerSamuel J.bDowdKimberly A.cRobertsonShelly"/>
 <result pre="to coinfections in human immunodeficiency virus (HIV)-infected individuals are multifaceted." exact="ZIKV" post="and other flaviviruses are sensitive to neutralizing antibodies, whose"/>
 <result pre="adaptive immune responses which become perturbed in HIV-infected individuals influence" exact="ZIKV" post="infection. Abstract ABSTRACT Flaviviruses are controlled by adaptive immune"/>
 <result pre="flavivirus clearance and pathogenesis is unclear. Here, we studied how" exact="Zika" post="virus (ZIKV) infection is modulated in SIV-infected nonhuman primates."/>
 <result pre="(ZIKV) infection is modulated in SIV-infected nonhuman primates. We measured" exact="ZIKV" post="replication, cellular ZIKV RNA levels, and immune responses in"/>
 <result pre="modulated in SIV-infected nonhuman primates. We measured ZIKV replication, cellular" exact="ZIKV" post="RNA levels, and immune responses in non-SIV-infected and SIV-infected"/>
 <result pre="Coinfected animals had a 1- to 2-day delay in peak" exact="ZIKV" post="viremia, which was 30% of that in non-SIV-infected animals."/>
 <result pre="viremia, which was 30% of that in non-SIV-infected animals. However," exact="ZIKV" post="viremia was significantly prolonged in SIV-positive (SIV+) RMs. ISG"/>
 <result pre="in SIV-positive (SIV+) RMs. ISG levels at the time of" exact="ZIKV" post="infection were predictive for lower ZIKV viremia in the"/>
 <result pre="at the time of ZIKV infection were predictive for lower" exact="ZIKV" post="viremia in the SIV+ RMs, while prolonged ZIKV viremia"/>
 <result pre="for lower ZIKV viremia in the SIV+ RMs, while prolonged" exact="ZIKV" post="viremia was associated with muted and delayed adaptive responses"/>
 <result pre="muted and delayed adaptive responses in SIV+ RMs. KEYWORDS SIV" exact="ZIKV" post="innate immunity type I interferon Funding HHS | NIH"/>
 <result pre="table-count: equation-count: ref-count: page-count: word-count: INTRODUCTION The high prevalence of" exact="Zika" post="virus (ZIKV) in northeast Brazil and its spread in"/>
 <result pre="infection and microcephaly in fetuses of ZIKV-infected mothers (3–5). Since" exact="ZIKV" post="and other flaviviruses are transmitted by arthropods, flavivirus epidemics"/>
 <result pre="areas with a high incidence of HIV infection (6, 7)." exact="ZIKV" post="and other flaviviruses are sensitive to type I interferons"/>
 <result pre="other flaviviruses are sensitive to type I interferons (IFNs). Indeed," exact="ZIKV" post="replicates poorly in immunocompetent mice (8–10), in part due"/>
 <result pre="mice (8–10), in part due to an inability of the" exact="ZIKV" post="nonstructural 5 (NS5) protein to degrade mouse STAT2 (11–13)."/>
 <result pre="of over 300 IFN-stimulated genes (ISGs) (13). Mouse models of" exact="ZIKV" post="infection, therefore, generally require type I IFN signaling to"/>
 <result pre="immune responses are also clearly important for the clearance of" exact="ZIKV" post="and other flaviviruses (19–21). Human immunodeficiency virus (HIV) infection"/>
 <result pre="I IFN production which occurs in HIV infection might limit" exact="ZIKV" post="replication. Both ZIKV and SIV have individually been isolated"/>
 <result pre="which occurs in HIV infection might limit ZIKV replication. Both" exact="ZIKV" post="and SIV have individually been isolated from wild nonhuman"/>
 <result pre="disease progression (42–45). To explore how HIV infection might impact" exact="ZIKV" post="antiviral responses and disease progression, we followed ZIKV viremia,"/>
 <result pre="might impact ZIKV antiviral responses and disease progression, we followed" exact="ZIKV" post="viremia, ZIKV RNA levels within cells targeted by ZIKV"/>
 <result pre="ZIKV antiviral responses and disease progression, we followed ZIKV viremia," exact="ZIKV" post="RNA levels within cells targeted by ZIKV in vivo,"/>
 <result pre="followed ZIKV viremia, ZIKV RNA levels within cells targeted by" exact="ZIKV" post="in vivo, and innate and adaptive immune responses in"/>
 <result pre="SIV-infected RMs that were infected with ZIKV. We found that" exact="ZIKV" post="viremia peaked later and was prolonged in SIV-coinfected RMs."/>
 <result pre="These data provide insight into how preexisting lentiviral infection modulates" exact="ZIKV" post="viremia in a relevant NHP model for both infections."/>
 <result pre="SIV infection might influence viremia and the host response to" exact="ZIKV" post="infection, we infected 7 Asian RMs with 3,000 50%"/>
 <result pre="thereafter, we subcutaneously infected these animals with 104 PFU of" exact="ZIKV" post="isolate Nicaragua/2016 (SIV/ZIKV animals) (Table 1). For a control,"/>
 <result pre="a control, we also infected 12 rhesus macaques (RMs) with" exact="ZIKV" post="only (Table 1). The time point 3 weeks post-SIV"/>
 <result pre="nodes at numerous time points both pre- and post-SIV and/or" exact="ZIKV" post="infection (Fig. 1A) to study viremia and innate and"/>
 <result pre="a significant loss of memory CD4+ T cells prior to" exact="ZIKV" post="challenge (Fig. 1B) (P = 0.0156), consistent with these animals being"/>
 <result pre="(P = 0.0156), consistent with these animals being progressively SIV infected, but" exact="ZIKV" post="infection did not exacerbate the loss of CD4+ T"/>
 <result pre="12 SIV/ZIKV 2,300,000 A01+ B08– B17– RH37073 Female 10.2 12" exact="ZIKV" post="NA A01+ B08– B17+ RH788 Male 16.5 13 ZIKV"/>
 <result pre="12 ZIKV NA A01+ B08– B17+ RH788 Male 16.5 13" exact="ZIKV" post="NA A01– B08– B17– RHDF86 Male 13.2 6 ZIKV"/>
 <result pre="13 ZIKV NA A01– B08– B17– RHDF86 Male 13.2 6" exact="ZIKV" post="NA A01– B08– B17– RHDBC4 Male 14.9 13 ZIKV"/>
 <result pre="6 ZIKV NA A01– B08– B17– RHDBC4 Male 14.9 13" exact="ZIKV" post="NA A01– B08– B17– RHA0P003 Male 13.3 18 ZIKV"/>
 <result pre="13 ZIKV NA A01– B08– B17– RHA0P003 Male 13.3 18" exact="ZIKV" post="NA ND RH734 Male 12.0 16 ZIKV NA A01–"/>
 <result pre="Male 13.3 18 ZIKV NA ND RH734 Male 12.0 16" exact="ZIKV" post="NA A01– B08– B17– RHZJ31 Male 7.2 7 ZIKV"/>
 <result pre="16 ZIKV NA A01– B08– B17– RHZJ31 Male 7.2 7" exact="ZIKV" post="NA ND RHZG41 Female 5.6 10 ZIKV NA A01–"/>
 <result pre="Male 7.2 7 ZIKV NA ND RHZG41 Female 5.6 10" exact="ZIKV" post="NA A01– B08– B17– RHDF0B Male 8.6 4 ZIKV"/>
 <result pre="10 ZIKV NA A01– B08– B17– RHDF0B Male 8.6 4" exact="ZIKV" post="NA ND RHDF2H Male 4.7 4 ZIKV NA ND"/>
 <result pre="Male 8.6 4 ZIKV NA ND RHDF2H Male 4.7 4" exact="ZIKV" post="NA ND RHDFWF Male 4.9 4 ZIKV NA ND"/>
 <result pre="Male 4.7 4 ZIKV NA ND RHDFWF Male 4.9 4" exact="ZIKV" post="NA ND RHDFWL Male 4.7 5 ZIKV NA ND"/>
 <result pre="Male 4.9 4 ZIKV NA ND RHDFWL Male 4.7 5" exact="ZIKV" post="NA ND aNA, not applicable; ND, not determined. bThe"/>
 <result pre="SIV RNA per milliliter of plasma at day 0 of" exact="ZIKV" post="infection. FIG 1 Effect of SIV coinfection on ZIKV"/>
 <result pre="of ZIKV infection. FIG 1 Effect of SIV coinfection on" exact="ZIKV" post="viremia and cellular infection in peripheral lymph nodes. (A)"/>
 <result pre="(A) Study design depicting longitudinal time points for SIV infection," exact="ZIKV" post="infection, and PBMC and peripheral LN sampling. (B) Memory"/>
 <result pre="peripheral LN sampling. (B) Memory CD4+ T cell counts for" exact="ZIKV" post="(blue squares; n = 6) and SIV/ZIKV animals (red circles; n = 7)."/>
 <result pre="(red circles; n = 7). Each line represents an individual animal. (C)" exact="ZIKV" post="mean viral titer in plasma (ZIKV, n = 12; SIV/ZIKV, n = 7)."/>
 <result pre="from day 2 (d2) to day 7. (D and E)" exact="ZIKV" post="RNA per 1,000 sorted cells in peripheral LN T"/>
 <result pre="and 27 days post-ZIKV infection (E) in SIV/ZIKV-coinfected animals (red) and" exact="ZIKV" post="animals (blue). (F) Representative lymph node immunohistochemistry images at"/>
 <result pre="lymph node immunohistochemistry images at day 27 post-ZIKV infection of" exact="ZIKV" post="vRNA (RNAscope; red), CD20 (B cell follicle; green), CD68"/>
 <result pre="green), CD68 (white), and DAPI (blue). (G) Percentages of the" exact="ZIKV" post="probe signal that are found within the B cell"/>
 <result pre="post-ZIKV infection. (H) Quantification of the LN area positive for" exact="ZIKV" post="vRNA probe per total LN area quantified at day"/>
 <result pre="within the same group represent Wilcoxon matched-pair results. Peak plasma" exact="ZIKV" post="viremia is delayed in SIV-infected RMs. We next measured"/>
 <result pre="viremia is delayed in SIV-infected RMs. We next measured plasma" exact="ZIKV" post="viremia between animals that were and were not SIV"/>
 <result pre="Consistently with the results of previous reports, in non-SIV-infected RMs," exact="ZIKV" post="RNA was detectable in plasma by 2 days postinfection (dpi),"/>
 <result pre="undetectable levels by 7 dpi (47–53). In contrast, the dynamics of" exact="ZIKV" post="viremia were delayed in SIV-infected animals (Fig. 1C; see"/>
 <result pre="were delayed in SIV-infected animals (Fig. 1C; see also the" exact="ZIKV" post="viremia in individual animals discussed in Fig. S1 in"/>
 <result pre="animals discussed in Fig. S1 in the supplemental material). Peak" exact="ZIKV" post="RNA in SIV-infected animals occurred at approximately 4 days postinfection"/>
 <result pre="in non-SIV-infected animals. Furthermore, the SIV-infected RMs had significantly lower" exact="ZIKV" post="plasma RNA at both day 2 (Fig. 1C) ("/>
 <result pre="post-ZIKV infection. Likely as a consequence of this delayed peak," exact="ZIKV" post="RNA levels were higher in SIV+ animals than in"/>
 <result pre="SIV+ animals than in SIV-negative animals at day 7 after" exact="ZIKV" post="infection, a time when ZIKV had been cleared from"/>
 <result pre="animals at day 7 after ZIKV infection, a time when" exact="ZIKV" post="had been cleared from most non-SIV-infected RMs (Fig. 1C)"/>
 <result pre="while solid lines represent the mean viral titer for the" exact="ZIKV" post="cohort (blue; n = 12) and the SIV/ZIKV cohort (red; n = 7)."/>
 <result pre="may apply. Peripheral lymph node macrophages are a source of" exact="ZIKV" post="replication. To understand ZIKV tropism in our coinfection model,"/>
 <result pre="node macrophages are a source of ZIKV replication. To understand" exact="ZIKV" post="tropism in our coinfection model, we used flow cytometry"/>
 <result pre="cytometric sorting strategy is shown in Fig. S2) and measured" exact="ZIKV" post="RNA by quantitative reverse transcription-PCR (qRT-PCR). We found ZIKV"/>
 <result pre="measured ZIKV RNA by quantitative reverse transcription-PCR (qRT-PCR). We found" exact="ZIKV" post="RNA in lymph node-resident macrophages and, to a lesser"/>
 <result pre="a lesser extent, in B cells, with higher levels of" exact="ZIKV" post="RNA in macrophages isolated from non-SIV-infected animals at day"/>
 <result pre="than in SIV-infected animals ( P = 0.021). Interestingly, we also found" exact="ZIKV" post="RNA in macrophages isolated from LNs of animals at"/>
 <result pre="at day 27 post-ZIKV infection, a time point when plasma" exact="ZIKV" post="RNA was undetectable in plasma (Fig. 1E). This is"/>
 <result pre="This is consistent with previous reports of the persistence of" exact="ZIKV" post="in the lymph nodes of RMs, with virus being"/>
 <result pre="infection status by RT-PCR. A representative staining profile from the" exact="ZIKV" post="cohort is shown. Live, singlet leukocytes were sorted into"/>
 <result pre="States. Foreign copyrights may apply. Fluorescence in situ hybridization for" exact="ZIKV" post="RNA in lymph node sections verified that ZIKV RNA"/>
 <result pre="hybridization for ZIKV RNA in lymph node sections verified that" exact="ZIKV" post="RNA could be detected both within B cell follicles"/>
 <result pre="B cell follicles and in the paracortex (Fig. 1F, where" exact="ZIKV" post="RNA is indicated with red arrows), with the majority"/>
 <result pre="is indicated with red arrows), with the majority of the" exact="ZIKV" post="RNA at days 5 and day 27 post-ZIKV infection"/>
 <result pre="follicle (Fig. 1G). To understand how lymph node levels of" exact="ZIKV" post="RNA compared between SIV+ and non-SIV-infected animals, we performed"/>
 <result pre="image analysis (Fig. 1G and H). Consistently with our plasma" exact="ZIKV" post="RNA analysis, we observed modestly higher levels of ZIKV"/>
 <result pre="plasma ZIKV RNA analysis, we observed modestly higher levels of" exact="ZIKV" post="RNA within lymph nodes of non-SIV-infected animals at day"/>
 <result pre="SIV+ animals (P = 0.056) (Fig. 1H) but significantly higher levels of" exact="ZIKV" post="RNA in lymph nodes of SIV+ animals at day"/>
 <result pre="(Fig. 1H). These data are consistent with delayed clearance of" exact="ZIKV" post="in SIV+ animals and further demonstrate that the LN"/>
 <result pre="and further demonstrate that the LN serves as a prolonged" exact="ZIKV" post="reservoir in RMs. SIV coinfection reduces immune responses to"/>
 <result pre="analysis, we next measured innate and adaptive immunological responses during" exact="ZIKV" post="infection of the animals in our cohort (the flow"/>
 <result pre="found that RMs mounted robust proliferative responses to SIV and" exact="ZIKV" post="infections in several cellular populations as measured by Ki67"/>
 <result pre="mounted NK cell proliferative responses to both SIV infection and" exact="ZIKV" post="infection (Fig. 2A). However, the NK cell proliferative response"/>
 <result pre="infection (Fig. 2A). However, the NK cell proliferative response during" exact="ZIKV" post="replication among the SIV+ animals was restricted compared to"/>
 <result pre="the Ki67+ memory CD8+ T cell population (P = 0.0368 in the" exact="ZIKV" post="cohort and P = 0.0009 in the SIV/ZIKV cohort). We did"/>
 <result pre="SIV/ZIKV cohort). We did not observe any proliferative response to" exact="ZIKV" post="among B cells (Fig. 2D). SIV infection was also"/>
 <result pre="(Fig. 2). Proliferative responses of T and B cells to" exact="ZIKV" post="infection among SIV+ animals were, thus, less clear given"/>
 <result pre="memory (mem) B cells (D) longitudinally pre- and post-ZIKV infection." exact="ZIKV" post="cohort mean percentages are illustrated by blue squares (n = 6),"/>
 <result pre="Error bars represent standard deviations for each time point. (E)" exact="Zika" post="virus-neutralizing antibody titers (EC50 values) post-ZIKV infection in ZIKV"/>
 <result pre="(E) Zika virus-neutralizing antibody titers (EC50 values) post-ZIKV infection in" exact="ZIKV" post="RMs (blue squares; n = 5) and SIV/ZIKV RMs (red circles;"/>
 <result pre="the analysis of PBMCs. A representative staining profile from the" exact="ZIKV" post="cohort is shown. Live, singlet lymphocytes were phenotypically characterized"/>
 <result pre="longitudinal plasma samples (Fig. 2E). In non-SIV-infected animals, NAbs to" exact="ZIKV" post="became detectable by day 7 post-ZIKV infection and then"/>
 <result pre="56 (Fig. 2E). In SIV/ZIKV-coinfected RMs, the NAb response to" exact="ZIKV" post="was slightly delayed and peaked at a lower titer"/>
 <result pre="SIV-infected RMs have reduced innate and adaptive immune responses to" exact="ZIKV" post="infection. ZIKV has no significant effect on CD4 T"/>
 <result pre="have reduced innate and adaptive immune responses to ZIKV infection." exact="ZIKV" post="has no significant effect on CD4 T cell functionality"/>
 <result pre="the maintenance and development of Th1 cells (57). Given that" exact="ZIKV" post="is also an RNA virus which induces Th1 cells"/>
 <result pre="which induces Th1 cells (58), we sought to explore whether" exact="ZIKV" post="coinfection further exacerbates immune dysfunction. Thus, we assessed whether"/>
 <result pre="CD40L, IL-22, IL-2, and TNF-α) of Th17 cells (Fig. 3B)." exact="ZIKV" post="infection did not influence the functional capacity of memory"/>
 <result pre="IL-2, and TNF-α (B) in SIV/ZIKV (top pie charts)- and" exact="ZIKV" post="(bottom pie charts)-infected RMs prior to and after infection"/>
 <result pre="are listed as not significant (NS). Interferon signaling predicts peak" exact="ZIKV" post="plasma viremia. The observed delays in both ZIKV viremia"/>
 <result pre="predicts peak ZIKV plasma viremia. The observed delays in both" exact="ZIKV" post="viremia and immunological responses in coinfected RMs suggested that"/>
 <result pre="that SIV viremia might, itself, either directly or indirectly limit" exact="ZIKV" post="replication. However, when we compared SIV plasma viral loads"/>
 <result pre="we compared SIV plasma viral loads at day 0 of" exact="ZIKV" post="infection with ZIKV plasma viral loads at day 3"/>
 <result pre="plasma viral loads at day 0 of ZIKV infection with" exact="ZIKV" post="plasma viral loads at day 3 post-ZIKV infection (peak"/>
 <result pre="ZIKV plasma viral loads at day 3 post-ZIKV infection (peak" exact="ZIKV" post="viremia in non-SIV-infected animals) we found no clear evidence"/>
 <result pre="evidence that SIV viremia correlates with the extent of subsequent" exact="ZIKV" post="replication (Fig. 4A) (r = –0.1081, P = 0.8190). Considering that"/>
 <result pre="whether there was an association of ISGs with levels of" exact="ZIKV" post="viremia in our SIV/ZIKV animals. To measure systemic levels"/>
 <result pre="levels of IP-10/CXCL10 in our animals longitudinally after SIV and" exact="ZIKV" post="infections (Fig. 4B). This IFN-induced protein has been shown"/>
 <result pre="individuals and strongly associated with exanthema (63). In non-SIV-infected animals," exact="ZIKV" post="infection led to increased plasma levels of IP-10 that"/>
 <result pre="elicited by SIV infection might predict lower levels of peak" exact="ZIKV" post="viremia and compared the plasma levels of IP-10 prior"/>
 <result pre="viremia and compared the plasma levels of IP-10 prior to" exact="ZIKV" post="infection with the levels of ZIKV viremia at day"/>
 <result pre="of IP-10 prior to ZIKV infection with the levels of" exact="ZIKV" post="viremia at day 3 (Fig. 4C). Higher levels of"/>
 <result pre="day 3 (Fig. 4C). Higher levels of IP-10 prior to" exact="ZIKV" post="infection, produced in response to SIV infection, were predictive"/>
 <result pre="response to SIV infection, were predictive of lower levels of" exact="ZIKV" post="viremia. Moreover, the prolonged ZIKV viremia observed in SIV/ZIKV-coinfected"/>
 <result pre="predictive of lower levels of ZIKV viremia. Moreover, the prolonged" exact="ZIKV" post="viremia observed in SIV/ZIKV-coinfected RMs at day 7 post-ZIKV"/>
 <result pre="infection was associated with plasma levels of IP-10 prior to" exact="ZIKV" post="infection (Fig. 4D). Thus, the IFN-stimulated response mounted against"/>
 <result pre="SIV correlated with a delayed peak and prolonged clearance of" exact="ZIKV" post="viremia. FIG 4 IFN-stimulated IP-10 gene levels are predictive"/>
 <result pre="FIG 4 IFN-stimulated IP-10 gene levels are predictive of peak" exact="ZIKV" post="plasma viremia. (A) Association between ZIKV plasma viremia (log10"/>
 <result pre="are predictive of peak ZIKV plasma viremia. (A) Association between" exact="ZIKV" post="plasma viremia (log10 GE/ml) at day 3 and SIV"/>
 <result pre="day 3 and SIV plasma viremia at day 0 of" exact="ZIKV" post="infection (7 RMs in the SIV/ZIKV cohort). VL, viral"/>
 <result pre="levels with standard deviation error bars are represented for the" exact="ZIKV" post="cohort (n = 6) in blue squares and for the SIV/ZIKV"/>
 <result pre="IP-10 plasma levels (picograms per milliliter) at day 0 of" exact="ZIKV" post="infection and ZIKV plasma viremia (log10 GE/ml) at day"/>
 <result pre="(picograms per milliliter) at day 0 of ZIKV infection and" exact="ZIKV" post="plasma viremia (log10 GE/ml) at day 3 (C) and"/>
 <result pre="SIV/ZIKV RM data points are shown as red circles, and" exact="ZIKV" post="RM data points are shown as blue squares. Spearman"/>
 <result pre="associations in panels A, C, and D. Transcriptional analysis of" exact="ZIKV" post="and SIV immune responses. Since we observed associations between"/>
 <result pre="we observed associations between increased IP-10 levels and lower peak" exact="ZIKV" post="viremia at day 3 post-Zika infection in our coinfected"/>
 <result pre="to explore global transcriptional responses that coincide with SIV and" exact="ZIKV" post="infection. Gene expression was measured from mRNAs extracted from"/>
 <result pre="Principal-component analysis revealed that transcript profiles of PBMCs from the" exact="ZIKV" post="RMs were distinct from those of the SIV/ZIKV RMs"/>
 <result pre="within the gene expression data was related to SIV or" exact="ZIKV" post="infection, most of which was attributable to SIV infection."/>
 <result pre="infection, most of which was attributable to SIV infection. While" exact="ZIKV" post="coinfection did not dramatically alter the transcriptional profile of"/>
 <result pre="dramatically alter the transcriptional profile of PBMCs from SIV-infected animals," exact="ZIKV" post="did alter the transcriptional profile of circulating leukocytes (Fig."/>
 <result pre="which were induced by SIV infection were also induced by" exact="ZIKV" post="infection, albeit to lower levels. Indeed, when we compared"/>
 <result pre="Indeed, when we compared non-SIV-infected and SIV-infected RMs prior to" exact="ZIKV" post="infection (ZIKV day 0), 163 genes were significantly differentially"/>
 <result pre="FIG 5 Transcriptional gene profiling of expression changes in acute" exact="ZIKV" post="infection. Immunology panel gene expression profiling in the ZIKV"/>
 <result pre="acute ZIKV infection. Immunology panel gene expression profiling in the" exact="ZIKV" post="RM cohort (n = 4) at day 0 (filled blue circles)"/>
 <result pre="RM. (B) Heatmap of 163 differentially expressed genes (P &amp;gt; 0.05) in" exact="ZIKV" post="and SIV/ZIKV RM cohorts (n = 4 and n = 5, respectively) at"/>
 <result pre="in plasma at day 0. (E to G) Associations between" exact="ZIKV" post="plasma viremia (log10 number of GE per milliliter) at"/>
 <result pre="(I). (D to I) Blue squares represent data from the" exact="ZIKV" post="cohort, and red circles represent data from the SIV/ZIKV"/>
 <result pre="analysis. 10.1128/mBio.02790-19.4FIG S4Transcriptional gene profiling of expression changes in acute" exact="ZIKV" post="infection. Immunology panel gene expression profiling in the ZIKV"/>
 <result pre="acute ZIKV infection. Immunology panel gene expression profiling in the" exact="ZIKV" post="RM cohort (n = 4) at day 0 (filled blue circles)"/>
 <result pre="may apply. 10.1128/mBio.02790-19.5TABLE S1Transcriptional gene expression differences between SIV/ZIKV and" exact="ZIKV" post="cohorts at day 0. Download Table S1, PDF file,"/>
 <result pre="I IFN response to SIV (Fig. 5C and Fig. S4B," exact="ZIKV" post="monoinfection). We compared levels of mRNA for IP-10/CXCL10 in"/>
 <result pre="association between levels of IP-10 mRNA at day 0 and" exact="ZIKV" post="viremia at day 3 (Fig. 5E), as we did"/>
 <result pre="message levels of interferon-stimulated IFIT3 as a predictor of subsequent" exact="ZIKV" post="peak viremia (Fig. 5F). To further understand the robustness"/>
 <result pre="these findings, we also examined and found a relationship between" exact="ZIKV" post="viremia and levels of IRF7, a central ISG (Fig."/>
 <result pre="the SIV-induced type I IFN response may lead to diminished" exact="ZIKV" post="viremia during coinfection. DISCUSSION NHPs are often used as"/>
 <result pre="limited. Here, we studied how preexisting SIV infection influences subsequent" exact="ZIKV" post="infection. We find that the type I IFN responses"/>
 <result pre="I IFN responses elicited in SIV-infected RMs correlates with reduced" exact="ZIKV" post="replication, that these coinfected animals mount inferior humoral responses"/>
 <result pre="humoral responses to ZIKV, and that these animals have delayed" exact="ZIKV" post="clearance. A recent study, using a small cohort of"/>
 <result pre="simian-human immunodeficiency virus (SHIV)- and SIV-infected RMs also found that" exact="ZIKV" post="viremia was uncharacteristically low during coinfection; however, the authors"/>
 <result pre="that SHIV/SIV infections did not dramatically influence the course of" exact="ZIKV" post="infection (64). This small study of only 4 Asian"/>
 <result pre="antiretroviral therapy (71). That we also find higher levels of" exact="ZIKV" post="RNA in the lymph node follicles than in the"/>
 <result pre="the paracortex (irrespective of coinfection) (Fig. 1G) coupled with delayed" exact="ZIKV" post="clearance (Fig. 1C) in SIV-coinfected animals suggests that replication-competent"/>
 <result pre="ZIKV clearance (Fig. 1C) in SIV-coinfected animals suggests that replication-competent" exact="ZIKV" post="may persist in lymphoid follicles and suggests that similar"/>
 <result pre="However, it is unclear which particular types of cells become" exact="ZIKV" post="RNA+ in lymphoid follicles or whether FDCs can become"/>
 <result pre="to a robust production of ISGs (37–41). While infection with" exact="ZIKV" post="was sufficient to induce expression of ISGs, the response"/>
 <result pre="generated in acute SIV infection far exceeded that induced by" exact="ZIKV" post="(Fig. 4B). The differences in ISG induction may be"/>
 <result pre="distinct differences between the duration of viremia and magnitude of" exact="ZIKV" post="infection, which is typically cleared from plasma within 7 days,"/>
 <result pre="demonstrate that the level of IP-10/CXCL10 at the time of" exact="ZIKV" post="infection predicts subsequent ZIKV replication (Fig. 4C and D),"/>
 <result pre="of IP-10/CXCL10 at the time of ZIKV infection predicts subsequent" exact="ZIKV" post="replication (Fig. 4C and D), the SIV-generated IFN response"/>
 <result pre="D), the SIV-generated IFN response was insufficient to completely prevent" exact="ZIKV" post="replication. Moreover, recent work suggests that particular ISGs may"/>
 <result pre="bind to flavivirus receptors (72–74), which may explain the delayed" exact="ZIKV" post="viremia that we observed in SIV+ animals. Paradoxically, this"/>
 <result pre="delayed antibody responses, in turn, may lead to moderately prolonged" exact="ZIKV" post="viremia in SIV+ animals. Interestingly, levels of IP-10 have"/>
 <result pre="to differentiate between patients with and without neurological complications after" exact="ZIKV" post="infection in Brazil and between infants with and without"/>
 <result pre="consistent with the idea that IFN signaling is associated with" exact="ZIKV" post="pathogenesis (78). Tfh cells are an important reservoir for"/>
 <result pre="SIV in our coinfection model may compromise the generation of" exact="ZIKV" post="antibodies. A combination of Tfh loss and ISG-mediated hypoantigenemia"/>
 <result pre="flaviviral coinfection is unclear, these data coupled with the prolonged" exact="ZIKV" post="viremia demonstrate that SIV infection shapes the resultant anti-ZIKV"/>
 <result pre="similarly compromised or biased during hyperacute infection. Delayed clearance of" exact="ZIKV" post="in SIV-infected RMs coupled with the higher levels of"/>
 <result pre="of virus within the lymphoid follicle might result in prolonged" exact="ZIKV" post="transmission risks. This may be related to antibody complex"/>
 <result pre="nucleotides1338 to 1317 of the SIVmac239gag gene (80). To assess" exact="ZIKV" post="RNA levels in the plasma of our study RMs,"/>
 <result pre="PCR using a TaqMan probe (Integrated DNA Technologies) targeting the" exact="ZIKV" post="E protein. ZIKV RNA levels were measured in all"/>
 <result pre="TaqMan probe (Integrated DNA Technologies) targeting the ZIKV E protein." exact="ZIKV" post="RNA levels were measured in all animals to at"/>
 <result pre="assays). Reporter virus particles (RVPs) incorporating the structural proteins of" exact="ZIKV" post="(strain H/PF/2013) (81), dengue virus 2 (DENV2; strain 16681)"/>
 <result pre="H/PF/2013) (81), dengue virus 2 (DENV2; strain 16681) (82), or" exact="West Nile" post="virus (WNV) lineage I (strain NY99) (83) were produced"/>
 <result pre="protein (GFP)-expressing replicon derived from a lineage II strain of" exact="WNV" post="as previously described (81–84). To determine virus titer, 2-fold"/>
 <result pre="antibody excess at informative points. Neutralization assays. For neutralization studies," exact="ZIKV" post="RVPs were mixed with serial dilutions of heat-inactivated macaque"/>
 <result pre="plasma per well), which was designated the limit of detection." exact="ZIKV" post="infection assessment in LN cells. Lymph node cells from"/>
 <result pre="B cell, and macrophage populations (Fig. S2) for assessment of" exact="ZIKV" post="viral RNA via qRT-PCR. RNA was extracted from sorted"/>
 <result pre="(Qiagen) with on-column DNase I treatment per the manufacturer’s instructions." exact="ZIKV" post="positive-strand RNA was measured by qRT-PCR using the primers"/>
 <result pre="slightly modified probe to more closely correspond to the Nicaragua" exact="ZIKV" post="sequence (86). The following primer and probe sequences were"/>
 <result pre="instrument (ThermoFisher). A standard curve was generated using in vitro-transcribed" exact="ZIKV" post="RNA using an Ambion MEGAscript kit (ThermoFisher) and a"/>
 <result pre="MEGAscript kit (ThermoFisher) and a pCRII-TOPO plasmid containing French Polynesia" exact="ZIKV" post="bases 700 to 1500 (kindly provided by Thomas C."/>
 <result pre="curve was used to extrapolate the number of copies of" exact="ZIKV" post="RNA per 1,000 cells. Samples were considered positive if"/>
 <result pre="were biopsied 5 or 27 days post-ZIKV infection in both the" exact="ZIKV" post="and SIV/ZIKV cohorts. LNs were then fixed overnight in"/>
 <result pre="reagent kit (Advanced Cell Diagnostics) according to the manufacturer’s suggestions." exact="ZIKV" post="RNA was detected using the V-ZIKA-pp RNAscope probe, and"/>
 <result pre="Prism v7.0 software (GraphPad). Mann-Whitney U tests were used when" exact="Zika" post="mean titers and infection cell frequencies were compared between"/>
 <result pre="using the Mann-Whitney U test (Fig. 2). AUC analysis for" exact="Zika" post="mean titers was carried out similarly, except that it"/>
 <result pre="the curve defined by day 2 to day 7 of" exact="ZIKV" post="infection (Fig. 1C). Comparisons of ZIKV 50% effective concentrations"/>
 <result pre="to day 7 of ZIKV infection (Fig. 1C). Comparisons of" exact="ZIKV" post="50% effective concentrations (EC50s) were analyzed via 2-way analysis"/>
 <result pre="(ANOVA) of log-transformed data (Fig. 2E). Responses to SIV and" exact="ZIKV" post="were determined by repeated-measures one-way ANOVA analysis (Fig. 2A"/>
 <result pre="then subsequently challenged subcutaneously on day 21 post-SIV infection with" exact="Zika" post="virus isolate Nicaragua/2016 (UCB 7420) at 104 PFU (SIV/ZIKV"/>
 <result pre="104 PFU (SIV/ZIKV cohort); 12 RMs were infected with the" exact="Zika" post="virus isolate Nicaragua/2016 alone (ZIKV cohort) (Table 1). This"/>
 <result pre="Zika virus isolate Nicaragua/2016 alone (ZIKV cohort) (Table 1). This" exact="ZIKV" post="challenge virus was chosen due to its relatively high"/>
 <result pre="sampling time points were chosen to focus extensively on early" exact="ZIKV" post="infection prior to clearance from plasma circulation, as well"/>
 <result pre="exception of RHA0P003, free of the presence of antibodies for" exact="West Nile" post="virus, dengue virus, and ZIKV prior to study infection."/>
 <result pre="presence of antibodies for West Nile virus, dengue virus, and" exact="ZIKV" post="prior to study infection. Neutralizing antibody titers from RHA0P003"/>
 <result pre="analysis in Fig. 2E due to clear evidence of prior" exact="WNV" post="infection detected in a prospective antibody-dependent enhancement WNV reporter"/>
 <result pre="of prior WNV infection detected in a prospective antibody-dependent enhancement" exact="WNV" post="reporter virus particle assay. The NAb titers from this"/>
 <result pre="Simian immunodeficiency virus infection of rhesus macaques results in delayed" exact="Zika" post="virus clearance. mBio 10:e02790-19. https://doi.org/10.1128/mBio.02790-19. ACKNOWLEDGMENTS We thank Heather"/>
 <result pre="RojasDP, MerlerS, MistryD, PolettiP, RossiL, BrayM, HalloranME, LonginiIMJr, VespignaniA2017Spread of" exact="Zika" post="virus in the Americas. Proc Natl Acad Sci U"/>
 <result pre="A114:E4334–E4343. doi:10.1073/pnas.1620161114.28442561 3.BarbiL, CoelhoAVC, AlencarLCA, CrovellaS2018Prevalence of Guillain-Barre syndrome among" exact="Zika" post="virus infected cases: a systematic review and meta-analysis. Braz"/>
 <result pre="de Souza KuchenbeckerR, SchmidtMI2017Infection-related microcephaly after the 2015 and 2016" exact="Zika" post="virus outbreaks in Brazil: a surveillance-based analysis. Lancet390:861–870. doi:10.1016/S0140-6736(17)31368-5.28647172"/>
 <result pre="a surveillance-based analysis. Lancet390:861–870. doi:10.1016/S0140-6736(17)31368-5.28647172 5.NascimentoOJM, da SilvaI2017Guillain-Barre syndrome and" exact="Zika" post="virus outbreaks. Curr Opin Neurol30:500–507. doi:10.1097/WCO.0000000000000471.28617719 6.SamyAM, ThomasSM, WahedAA,"/>
 <result pre="6.SamyAM, ThomasSM, WahedAA, CohoonKP, PetersonAT2016Mapping the global geographic potential of" exact="Zika" post="virus spread. Mem Inst Oswaldo Cruz111:559–560. doi:10.1590/0074-02760160149.27653360 7. 2017"/>
 <result pre="De La BarreraRA, JarmanRG, EckelsKH, MichaelNL, ThomasSJ, BarouchDH2016Vaccine protection against" exact="Zika" post="virus from Brazil. Nature536:474–478. doi:10.1038/nature18952.27355570 9.LazearHM, GoveroJ, SmithAM, PlattDJ,"/>
 <result pre="9.LazearHM, GoveroJ, SmithAM, PlattDJ, FernandezE, MinerJJ, DiamondMS2016A mouse model of" exact="Zika" post="virus pathogenesis. Cell Host Microbe19:720–730. doi:10.1016/j.chom.2016.03.010.27066744 10.RossiSL, TeshRB, AzarSR,"/>
 <result pre="PaesslerS, VasilakisN, WeaverSC2016Characterization of a novel murine model to study" exact="Zika" post="virus. Am J Trop Med Hyg94:1362–1369. doi:10.4269/ajtmh.16-0111.27022155 11.GrantA, PoniaSS,"/>
 <result pre="Viruses10:E712. doi:10.3390/v10120712.30558110 14.Alves Dos SantosE, FinkK2018Animal models for dengue and" exact="Zika" post="vaccine development. Adv Exp Med Biol1062:215–239. doi:10.1007/978-981-10-8727-1_16.29845536 15.GormanMJ, CaineEA,"/>
 <result pre="EbelGD, BaricRS, BestSM, ArtyomovMN, Garcia-SastreA, DiamondMS2018An immunocompetent mouse model of" exact="Zika" post="virus infection. Cell Host Microbe23:672–685.e6. doi:10.1016/j.chom.2018.04.003.29746837 16.BrassAL, HuangIC, BenitaY,"/>
 <result pre="IFITM proteins mediate cellular resistance to influenza A H1N1 virus," exact="West Nile" post="virus, and dengue virus. Cell139:1243–1254. doi:10.1016/j.cell.2009.12.017.20064371 17.JohnSP, ChinCR, PerreiraJM,"/>
 <result pre="doi:10.1128/JVI.00481-13.23658454 18.SavidisG, PerreiraJM, PortmannJM, MeranerP, GuoZ, GreenS, BrassAL2016The IFITMs inhibit" exact="Zika" post="virus replication. Cell Rep15:2323–2330. doi:10.1016/j.celrep.2016.05.074.27268505 19.AbbinkP, StephensonKE, BarouchDH2018Zika virus"/>
 <result pre="and therapy. Curr HIV/AIDS Rep12:41–53. doi:10.1007/s11904-014-0244-6.25662992 42.BradleyMP, NagamineCM2017Animal models of" exact="Zika" post="virus. Comp Med67:242–252.28662753 43.DudleyDM, AliotaMT, MohrEL, WeilerAM, Lehrer-BreyG, WeisgrauKL,"/>
 <result pre="CapuanoS, GolosTG, OsorioJE, FriedrichTC, O'ConnorDH2016A rhesus macaque model of Asian-lineage" exact="Zika" post="virus infection. Nat Commun7:12204. doi:10.1038/ncomms12204.27352279 44.EstesJD, WongSW, BrenchleyJM2018Nonhuman primate"/>
 <result pre="GaoGF, CaoWC, ShiPY, QinCF2016Characterization of a 2016 clinical isolate of" exact="Zika" post="virus in non-human primates. EBioMedicine12:170–177. doi:10.1016/j.ebiom.2016.09.022.27693104 51.O'ConnorMA, Tisoncik-GoJ, LewisTB,"/>
 <result pre="EdlefsenPT, SmedleyJ, KlattNR, GaleM, FullerDH2018Early cellular innate immune responses drive" exact="Zika" post="viral persistence and tissue tropism in pigtail macaques. Nat"/>
 <result pre="dynamics in rhesus macaques infected with a Brazilian strain of" exact="Zika" post="virus. J Immunol199:1003–1011. doi:10.4049/jimmunol.1700256.28667164 54.BrenchleyJM, PaiardiniM, KnoxKS, AsherAI, CervasiB,"/>
 <result pre="EckelsKH, ThomasSJ, MichaelNL, BarouchDH2017Durability and correlates of vaccine protection against" exact="Zika" post="virus in rhesus monkeys. Sci Transl Med9:eaao4163. doi:10.1126/scitranslmed.aao4163.29237759 59.AndersonJF,"/>
 <result pre="Med9:eaao4163. doi:10.1126/scitranslmed.aao4163.29237759 59.AndersonJF, RahalJJ2002Efficacy of interferon alpha-2b and ribavirin against" exact="West Nile" post="virus in vitro. Emerg Infect Dis8:107–108. doi:10.3201/eid0801.010252.11749765 60.CranceJM, ScaramozzinoN,"/>
 <result pre="Antiviral Res58:73–79. doi:10.1016/s0166-3542(02)00185-7.12719009 61.DiamondMS, RobertsTG, EdgilD, LuB, ErnstJ, HarrisE2000Modulation of" exact="Dengue" post="virus infection in human cells by alpha, beta, and"/>
 <result pre="activity of Sofosbuvir and type-I interferons (alpha and beta) against" exact="Zika" post="virus. J Med Virol90:8–12. doi:10.1002/jmv.24932.28851097 63.BarrosJBS, da SilvaPAN, KogaRCR,"/>
 <result pre="SilvaPAN, KogaRCR, Gonzalez-DiasP, Carmo FilhoJR, NagibPRA, CoelhoV, NakayaHI, FonsecaSG, PfrimerI2018Acute" exact="Zika" post="virus infection in an endemic area shows modest proinflammatory"/>
 <result pre="73.KimSY, ZhaoJ, LiuX, FraserK, LinL, ZhangX, ZhangF, DordickJS, LinhardtRJ2017Interaction of" exact="Zika" post="virus envelope protein with glycosaminoglycans. Biochemistry56:1151–1162. doi:10.1021/acs.biochem.6b01056.28151637 74.ChenY, MaguireT,"/>
 <result pre="KongWP, MascolaJR, PiersonTC, GrahamBS2016Rapid development of a DNA vaccine for" exact="Zika" post="virus. Science354:237–240. doi:10.1126/science.aai9137.27708058 76.GaudinskiMR, HouserKV, MorabitoKM, HuZ, YamshchikovG, RothwellRS,"/>
 <result pre="VRC 320 study teams. 2018Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
 <result pre="with neurological complications and congenital central nervous system abnormalities from" exact="Zika" post="virus-infected patients in Brazil. J Infect Dis216:172–181. doi:10.1093/infdis/jix261.28838147 79.OrtizAM,"/>
 <result pre="PlattDJ, MascolaJR, GrahamBS, MulliganMJ, DiamondMS, LedgerwoodJE, PiersonTC2016Broadly neutralizing activity of" exact="Zika" post="virus-immune sera identifies a single viral serotype. Cell Rep16:1485–1491."/>
 <result pre="DomsRW2006A rapid and quantitative assay for measuring antibody-mediated neutralization of" exact="West Nile" post="virus infection. Virology346:53–65. doi:10.1016/j.virol.2005.10.030.16325883 84.MukherjeeS, PiersonTC, DowdKA2014Pseudo-infectious reporter virus"/>
 <result pre="LavenJJ, VelezJO, LambertAJ, JohnsonAJ, StanfieldSM, DuffyMR2008Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007."/>
</results>
